Quick viewing(Text Mode)

Interactions with HBV Treatment

Interactions with HBV Treatment

www.hep-druginteractions.org

Interactions with HBV Treatment

Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 1 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, ; ETV, ; LAM, ; PEG IFN, Peginterferon; RBV, ; TBV, ; TAF, ; TDF, Tenofovir-DF.

ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b Anaesthetics & Muscle Relaxants Antibacterials (continued) Bupivacaine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cloxacillin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cisatracurium ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dapsone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Delamanid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ertapenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Propofol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ethambutol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Thiopental ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Flucloxacillin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆  Analgesics Imipenem   ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Levofloxacin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Linezolid ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lymecycline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆  Meropenem   ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

for distribution. for Methenamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Moxifloxacin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Diamorphine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nitrofurantoin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Norfloxacin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ofloxacin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Penicillin V ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Piperacillin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Pivmecillinam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Pyrazinamide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Rifabutin ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Rifapentine ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Spectinomycin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Streptomycin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  (Dipyrone) ◆ ◆ ◆ ⚫ ⚫ ⚫ ◆ ◆ ◆ Sulfadiazine ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆   ◆ ◆ ◆ ◆ Tazobactam   ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Telithromycin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Temocillin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ticarcillin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (Meperidine) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Trimethoprim/Sulfamethoxazole ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Troleandomycin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Vancomycin ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Anticoagulant, Antiplatelet & Fibrinolytic Anthelmintics Acenocoumarol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Albendazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Anagrelide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ivermectin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Apixaban ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Oxamniquine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Clopidogrel ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Praziquantel ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dabigatran ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Pyrantel ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dalteparin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Antiarrhythmics Danaparoid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Amiodarone ◆ ◆ ◆ ◆ ◆ ◆ ◆   Dipyridamole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Bepridil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Edoxaban ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Eltrombopag ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Disopyramide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Enoxaparin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dofetilide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Fluindione ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dronedarone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Fondaparinux ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Flecainide ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ Heparin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lidocaine (Lignocaine) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Phenprocoumon ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Mexiletine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Prasugrel ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Rivaroxaban ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   Streptokinase ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Vernakalant ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ticagrelor ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Antibacterials Ticlopidine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆  Tinzaparin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Amoxicillin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Warfarin ◆ ◆ ◆    ◆ ◆ ◆ Ampicillin ◆ ◆ ◆ ◆ ◆ Anticonvulsants Azithromycin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Carbamazepine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ⚫ ◆ Aztreonam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Clonazepam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Bedaquiline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Eslicarbazepine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Benzylpenicillin ◆ ◆ ◆ ◆ ◆ ◆ Ethosuximide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Capreomycin ◆ ◆ ◆ ◆ ◆  For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not Not only. use personal For distribution. for Not use only. personal For distribution. for Not only. use personal For Gabapentin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cefaclor ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lacosamide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cefadroxil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cefalexin   ◆ ◆ ◆ ◆ ◆ ◆  Cefazolin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Levetiracetam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cefixime ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Oxcarbazepine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ⚫ ◆ Cefotaxime ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Perampanel ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cefradine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Phenobarbital ◆ ◆ ◆ ◆ ◆ ◆ ◆ ⚫ ◆ Ceftaroline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Phenytoin ◆ ◆ ◆ ◆  ◆ ◆ ⚫ ◆ Ceftazidime ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Pregabalin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ceftriaxone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Primidone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ⚫ ◆ Cefuroxime ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Retigabine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Rufinamide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Sultiame ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Clarithromycin ◆ ◆ ◆ ◆ ◆ ◆ ◆   Tiagabine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Clavulanic acid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Topiramate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Clindamycin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (Divalproex) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Clofazimine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Vigabatrin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Zonisamide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

Key to symbols Notes ➢ Further information is available at © Liverpool Drug Interactions Group, ⚫ These drugs should not be coadministered www.hep-druginteractions.org University of Liverpool, Research Labs, Potential clinically significant interaction that is likely to require additional ➢ Predicted interactions are based on known 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF  monitoring, alteration of drug dosage or timing of administration metabolic pathways and routes of clearance. We aim to ensure that information is accurate and consistent with current knowledge Potential interaction likely to be of weak intensity. Additional ➢ Caution is required in patients with hepatic and practice. However, the University of Liverpool and its servants or agents shall action/monitoring or dosage adjustment is unlikely to be required impairment as this may also increase drug levels not be responsible or in any way liable for the continued currency of information in and require dose modification. this publication whether arising from negligence or otherwise howsoever or for any ◆ No clinically significant interaction expected ➢ Where advice differs between countries, the consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

charts reflect the more cautious option.

www.hep-druginteractions.org

Interactions with HBV Treatment

Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 2 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF.

ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Bilastine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Citalopram ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Desvenlafaxine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ebastine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Fexofenadine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Duloxetine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Escitalopram ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Levocetirizine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Fluvoxamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Terfenadine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

Imipramine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ distribution. for Lithium ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Antimigraine Agents ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Milnacipran ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Moclobemide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Methylergonovine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Sertraline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Antiprotozoals ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Amodiaquine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Venlafaxine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Artemether ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Artemisinin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Antidiabetics Artesunate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Acarbose ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Atovaquone ◆ ◆ ◆    ◆ ◆ ◆ Albiglutide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Chloroquine ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Alogliptin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dihydroartemisinin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Canagliflozin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Doxycycline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dapagliflozin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Halofantrine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dulaglutide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Hydroxychloroquine ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Empagliflozin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Lumefantrine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆ ◆ ◆ ◆ Exenatide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Mefloquine Nitazoxanide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Glibenclamide (Glyburide) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Pentamidine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Gliclazide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Primaquine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Proguanil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Glipizide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Pyrimethamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Insulin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Quinine ◆ ◆ ◆   ◆ ◆ ◆ ◆ Linagliptin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Sodium stibogluconate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Liraglutide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Sulfadoxine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lixisenatide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ /Neuroleptics Metformin ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nateglinide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Pioglitazone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Repaglinide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Saxagliptin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆    ◆ ◆ ◆   Sitagliptin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Tolbutamide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆ ◆ ◆ ◆ Vildagliptin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Amphotericin B ◆ ◆ ◆    ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Anidulafungin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Caspofungin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Fluconazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

Griseofulvin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Not only. use personal For distribution. for Not use only. personal For distribution. for Not only. use personal For ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isavuconazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nystatin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Voriconazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Zuclopentixol ◆ ◆ ◆   ◆ ◆ ◆ ◆

Key to symbols Notes ➢ Further information is available at © Liverpool Drug Interactions Group, ⚫ These drugs should not be coadministered www.hep-druginteractions.org University of Liverpool, Pharmacology Research Labs, Potential clinically significant interaction that is likely to require additional ➢ Predicted interactions are based on known 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF  monitoring, alteration of drug dosage or timing of administration metabolic pathways and routes of clearance. We aim to ensure that information is accurate and consistent with current knowledge Potential interaction likely to be of weak intensity. Additional ➢ Caution is required in patients with hepatic and practice. However, the University of Liverpool and its servants or agents shall action/monitoring or dosage adjustment is unlikely to be required impairment as this may also increase drug levels not be responsible or in any way liable for the continued currency of information in and require dose modification. this publication whether arising from negligence or otherwise howsoever or for any ◆ No clinically significant interaction expected ➢ Where advice differs between countries, the consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

charts reflect the more cautious option.

www.hep-druginteractions.org

Interactions with HBV Treatment

Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 3 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF.

ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b Antivirals Cancer Therapies   ◆ ◆ ◆ ◆ ◆ ◆  Abiraterone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆    ◆ ◆ ◆ Acalabrutinib ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Anastrozole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆    ◆ ◆  Avelumab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Favipiravir ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Axitinib ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Bevacizumab ◆ ◆ ◆    ◆ ◆ ◆ Oseltamivir   ◆ ◆ ◆ ◆ ◆ ◆ ◆ Blinatumomab ◆ ◆ ◆    ◆ ◆ ◆ Remdesivir ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Bosutinib ◆ ◆ ◆    ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆  Brentuximab vedotin ◆ ◆ ◆    ◆ ◆ ◆ Zanamivir ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆    ◆ Anxiolytics/Hypnotics/Sedatives Carboplatin ◆ ◆ ◆    ◆ ◆  Alprazolam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cetuximab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

Amobarbital ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Chlorambucil ◆ ◆ ◆    ◆ ◆ ◆ for distribution. for Bromazepam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cisplatin       ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cyclophosphamide ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Daratumumab ◆ ◆ ◆    ◆ ◆ ◆ Clobazam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Clorazepate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Doxorubicin ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Erlotinib ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Diazepam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Estramustine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Estazolam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Etoposide ◆ ◆ ◆    ◆ ◆ ◆ Flurazepam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Everolimus ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lorazepam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Exemestane ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lormetazepam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Fludarabine ◆ ◆ ◆    ◆ ◆ ◆ Midazolam (oral) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Gefitinib ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Midazolam (parenteral) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Gemcitabine ◆ ◆ ◆    ◆ ◆ ◆ Oxazepam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Idarubicin ◆ ◆ ◆    ◆ ◆ ◆ Quazepam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆    ◆ ◆ ◆ Temazepam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ipilimumab ◆ ◆ ◆    ◆ ◆ ◆ Triazolam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Irinotecan ◆ ◆ ◆    ◆ ◆ ◆ Zaleplon ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ixazomib ◆ ◆ ◆    ◆ ◆ ◆ Zolpidem ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lapatinib ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Zopiclone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Letrozole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Beta Blockers ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (oncology) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Mercaptopurine ◆ ◆ ◆   ⚫ ◆ ◆ ◆ ◆ ◆ ◆    ◆ ◆ ◆ Mesna   ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Methotrexate   ◆    ◆ ◆  ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Mitoxantrone Nilotinib ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Niraparib ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nivolumab ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Obinutuzumab ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ofatumumab ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Olaratumab ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Oxaliplatin    ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Paclitaxel ◆ ◆ ◆    ◆ ◆ ◆ Bisphosphonates Panitumumab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Alendronic acid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Rituximab ◆ ◆ ◆    ◆ ◆ ◆ Clodronate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ruxolitinib ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Sunitinib ◆ ◆ ◆    ◆ ◆ ◆ Pamidronate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Tamoxifen ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Risedronate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Temsirolimus ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Vinblastine ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Vincristine ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Vinorelbine ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Contraceptives and Replacements Conjugated ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (HRT) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (POP) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Desogestrel/ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆ ◆ ◆ ◆ (COC) Tiotropium ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (POP) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Calcium Channel Blockers

Amlodipine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Not only. use personal For distribution. for Not use only. personal For distribution. for Not only. use personal For Drospirenone/ (HRT) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Drospirenone/ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ethinylestradiol (COC) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ /estradiol Nicardipine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (HRT) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Estradiol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nisoldipine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ethinylestradiol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (implant) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   Etonogestrel (vaginal ring) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ /ethinylestradiol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (COC) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (Emergency Contraception)

Key to symbols Notes ➢ Further information is available at © Liverpool Drug Interactions Group, ⚫ These drugs should not be coadministered www.hep-druginteractions.org University of Liverpool, Pharmacology Research Labs, Potential clinically significant interaction that is likely to require additional ➢ Predicted interactions are based on known 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF  monitoring, alteration of drug dosage or timing of administration metabolic pathways and routes of clearance. We aim to ensure that information is accurate and consistent with current knowledge Potential interaction likely to be of weak intensity. Additional ➢ Caution is required in patients with hepatic and practice. However, the University of Liverpool and its servants or agents shall action/monitoring or dosage adjustment is unlikely to be required impairment as this may also increase drug levels not be responsible or in any way liable for the continued currency of information in and require dose modification. this publication whether arising from negligence or otherwise howsoever or for any ◆ No clinically significant interaction expected ➢ Where advice differs between countries, the consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

charts reflect the more cautious option.

www.hep-druginteractions.org

Interactions with HBV Treatment

Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 4 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF.

ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b Contraceptives and Hormone Replacements (continued) HCC Therapies Levonorgestrel (HRT) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lenvatinib ◆ ◆ ◆ ◆ ◆ ◆ Levonorgestrel (implant) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Pembrolizumab ◆ ◆ ◆  ◆ ◆ ◆ Levonorgestrel (IUD) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Regorafenib ◆ ◆ ◆ ◆ ◆ ◆ Levonorgestrel (POP) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Sorafenib ◆ ◆ ◆ ◆ ◆ ◆ Levonorgestrel/ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ B Drugs ethinylestradiol (COC) Adefovir ◆   ◆ ◆ ⚫ ⚫ Medroxyprogesterone (depot) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Entecavir ◆ ◆ ◆ ◆ ◆ ◆ ◆ Medroxyprogesterone (oral) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lamivudine ◆ ◆     ◆ ◆ Medroxyprogesterone/ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Peginterferon alfa-2a  ◆  n/a ◆ ⚫   (HRT) Peginterferon alfa-2b  ◆  n/a ◆ ⚫   Medroxyprogesterone/ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ribavirin ◆ ◆  ◆ ◆ ◆   estradiol (HRT) Telbivudine ◆ ◆  ⚫ ⚫ ◆ ◆  /ethinylestradiol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Tenofovir alafenamide (TAF) ⚫ ◆ ◆    ◆ ⚫ (patch) Tenofovir-DF ⚫ ◆ ◆     ⚫ distribution. for ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (Norethindrone) (depot injection) Hepatitis C Drugs (Direct Acting Antivirals) Norethisterone Daclatasvir ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (Norethindrone) (POP) Elbasvir/Grazoprevir ◆ ◆ ◆   ◆ ◆ ◆ ◆ Norethisterone Glecaprevir/Pibrentasvir ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (Norethindrone)/estradiol (HRT) Ledipasvir/Sofosbuvir ◆ ◆ ◆   ◆ ◆ ◆  Norethisterone OBV/PTV/r ◆ ◆ ◆   ◆ ◆  ◆ (Norethindrone)/ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ OBV/PTV/r + Dasabuvir ◆ ◆ ◆   ◆ ◆  ◆ ethinylestradiol (COC) Simeprevir ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Norethisterone Sofosbuvir (SOF) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (Norethindrone)/mestranol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ SOF/Velpatasvir ◆ ◆ ◆   ◆ ◆ ◆  (COC) SOF/Velpatasvir/Voxilaprevir ◆ ◆ ◆    ◆ ◆  /ethinylestradiol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Hepatitis D Entry Inhibitor (COC) Bulevirtide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ /conjugated ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ estrogens (HRT) Herbals/Supplements/Vitamins Aloe vera ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Norgestrel/ethinylestradiol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (COC) Ascorbic acid (Vitamin C) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Black cohosh (A. racemosa) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Agents ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cat’s claw (U. tomentosa) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Colecalciferol (Vitamin D3) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cyanocobalamin (B12) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Diosmin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Gastrointestinal Agents Echinacea ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aluminium hydroxide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Eucalyptus globulus ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ citrate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ferrous sulphate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Antacids ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Folic acid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aprepitant ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Garlic ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ginger (Z. officinale) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Ginkgo biloba ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ginseng ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Goldenseal (H. canadensis) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Grape seed extract ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Grapefruit juice ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Green tea (C. sinensis) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Esomeprazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Homeopathic remedies ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Famotidine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Inula racemosa ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Hyoscine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Iodine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ispaghula husk ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ kava (P. methysticum) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Milk thistle ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lansoprazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (Vitamin A) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Riboflavin (Vitamin B2) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Serenoa repens ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ St John’s wort ◆ ◆ ◆   ◆ ◆ ⚫ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Thiamine (Vitamin B1) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Turmeric () ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Methylcellulose ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

Omeprazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

Ondansetron ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not Not only. use personal For distribution. for Not use only. personal For distribution. for Not only. use personal For Pantoprazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Rabeprazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Senna ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Sulfasalazine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Trimebutine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

Key to symbols Notes ➢ Further information is available at © Liverpool Drug Interactions Group, ⚫ These drugs should not be coadministered www.hep-druginteractions.org University of Liverpool, Pharmacology Research Labs, Potential clinically significant interaction that is likely to require additional ➢ Predicted interactions are based on known 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF  monitoring, alteration of drug dosage or timing of administration metabolic pathways and routes of clearance. We aim to ensure that information is accurate and consistent with current knowledge Potential interaction likely to be of weak intensity. Additional ➢ Caution is required in patients with hepatic and practice. However, the University of Liverpool and its servants or agents shall action/monitoring or dosage adjustment is unlikely to be required impairment as this may also increase drug levels not be responsible or in any way liable for the continued currency of information in and require dose modification. this publication whether arising from negligence or otherwise howsoever or for any ◆ No clinically significant interaction expected ➢ Where advice differs between countries, the consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

charts reflect the more cautious option.

www.hep-druginteractions.org

Interactions with HBV Treatment

Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 5 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF.

ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b HIV Drugs / Agents Entry/Integrase Inhibitors ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Bictegravir/FTC/TAF ⚫ ◆ ⚫     ⚫ ⚫ Aliskiren ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dolutegravir ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Ambrisentan ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dolutegravir/rilpivirine ◆ ◆  ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Azilsartan ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Elvitegravir/cobi /FTC/TAF ⚫ ◆ ⚫     ⚫ ⚫ Benazepril ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Elvitegravir/cobi/FTC/TDF ⚫ ◆ ⚫     ⚫ ⚫ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Ibalizumab-uiyk ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Bosentan ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Maraviroc ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆  Raltegravir ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ NNRTIs Captopril   ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dolutegravir/rilpivirine ◆ ◆  ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Doravirine ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Doravirine/3TC/TDF ⚫ ◆ ⚫     ⚫ ⚫ Cilazapril ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Clevidipine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

for distribution. for ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Etravirine ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nevirapine ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Enalapril ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Rilpivirine ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Rilpivirine/FTC/TAF ⚫ ◆ ⚫   ◆  ⚫ ⚫ Epoprostenol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ NRTIs Eprosartan ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆     ◆ ◆ Fosinopril ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Didanosine ◆ ◆ ◆ ⚫ ⚫ ⚫   ⚫   ◆ ◆ ◆ ◆ ◆ ◆ Emtricitabine (FTC)  ◆ ⚫     ◆ ◆ Hydralazine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆  Emtricitabine + TAF ⚫ ◆ ⚫     ⚫ ⚫ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Emtricitabine + TDF ⚫ ◆ ⚫   ◆  ⚫ ⚫ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆     Lamivudine ◆ ◆ ◆ ◆ ◆ Irbesartan ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Stavudine  ◆ ◆   ⚫  ◆ ◆ Isradipine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Tenofovir-DF ⚫ ◆ ◆     ⚫ Ivabradine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ⚫ ⚫ ⚫  ◆ ◆ Lacidipine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Protease Inhibitors Lercanidipine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Atazanavir alone ◆ ◆ ◆ ◆ ◆    ⚫ Lisinopril ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Atazanavir/cobicistat ◆ ◆ ◆ ◆ ◆     Losartan ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Atazanavir + ◆ ◆ ◆ ◆ ◆     Macitentan ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Darunavir/cobicistat ◆ ◆ ◆ ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Darunavir/cobi/FTC/TAF ⚫ ◆ ⚫   ◆  ⚫ ⚫ Moxonidine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Darunavir + ritonavir ◆ ◆ ◆ ◆ ◆ ◆    Olmesartan ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Fosamprenavir ◆ ◆ ◆ ◆ ◆ ◆    Perindopril ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lopinavir ◆ ◆ ◆ ◆ ◆ ◆    Quinapril ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ritonavir ◆ ◆ ◆ ◆ ◆ ◆    Ramipril ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Tipranavir ◆ ◆ ◆ ◆ ◆ ◆  ⚫  ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Riociguat ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Sildenafil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Tadalafil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Telmisartan ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Trandolapril ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Valsartan ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Zofenopril ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not Not only. use personal For distribution. for Not use only. personal For distribution. for Not only. use personal For

Key to symbols Notes ➢ Further information is available at © Liverpool Drug Interactions Group, ⚫ These drugs should not be coadministered www.hep-druginteractions.org University of Liverpool, Pharmacology Research Labs, Potential clinically significant interaction that is likely to require additional ➢ Predicted interactions are based on known 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF  monitoring, alteration of drug dosage or timing of administration metabolic pathways and routes of clearance. We aim to ensure that information is accurate and consistent with current knowledge Potential interaction likely to be of weak intensity. Additional ➢ Caution is required in patients with hepatic and practice. However, the University of Liverpool and its servants or agents shall action/monitoring or dosage adjustment is unlikely to be required impairment as this may also increase drug levels not be responsible or in any way liable for the continued currency of information in and require dose modification. this publication whether arising from negligence or otherwise howsoever or for any ◆ No clinically significant interaction expected ➢ Where advice differs between countries, the consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

charts reflect the more cautious option.

www.hep-druginteractions.org

Interactions with HBV Treatment

Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 6 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF.

ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b Illicit/Recreational Other Drugs ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Acamprosate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆  Cannabis ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Acitretin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Activated charcoal ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Allopurinol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ecstasy (MDMA) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

GHB (Gamma-hydroxybutyrate) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Baclofen ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Heroin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Bamlanivimab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ LSD (Lysergic acid diethylamide) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Benralizumab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Mephedrone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Betahistine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Methamphetamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (PCP) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

Immunosuppressants Brinzolamide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ for distribution. for Adalimumab ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Alemtuzumab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Calcitonin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Anakinra ◆ ◆ ◆    ◆ ◆ ◆ Calcium carbimide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Calcium resonium ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Azathioprine ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Baricitinib ◆ ◆ ◆    ◆ ◆ ◆ Carbimazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Basiliximab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Carisoprodol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Brodalumab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Casirivimab/imdevimab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Canakinumab ◆ ◆ ◆    ◆ ◆ ◆ Cilostazol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ciclosporin ◆ ◆ ◆ ◆ ◆ ◆    Clomifene ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Eculizumab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Colchicine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Etanercept ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Colestyramine ◆ ◆ Fingolimod ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lenalidomide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Convalescent plasma (COVID- ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ 19) Mycophenolate ◆ ◆ ◆    ◆ ◆  COVID-19 vaccinations ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Pirfenidone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Sarilumab ◆ ◆ ◆    ◆ ◆ ◆ Cytisine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Sirolimus ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Darbepoetin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Tacrolimus ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Deferiprone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Tocilizumab ◆ ◆ ◆    ◆ ◆ ◆ Denosumab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Upadacitinib ◆ ◆ ◆    ◆ ◆ ◆ Dexamfetamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lipid Lowering Agents ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Alirocumab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Disulfiram ◆ ◆ ◆   ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Atorvastatin ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Donepezil Dorzolamide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Bezafibrate ◆ ◆ ◆ ◆ ◆ ◆  ◆  Dupilumab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Evolocumab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Eliglustat ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Emicizumab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Fenofibrate ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Epoetin alfa ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Fish oils ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Etelcalcetide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Fluvastatin ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Febuxostat ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Gemfibrozil ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Filgrastim ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lovastatin ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Pitavastatin ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Gadopentetate (gadolinium) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Pravastatin ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ phenylbutyrate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Rosuvastatin ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Goserelin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Simvastatin ◆ ◆ ◆ ◆ ◆ ◆  ◆ ◆ Influenza vaccine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ beta ◆ ◆ ◆ ⚫ ⚫  ◆ ◆ ◆

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not Not only. use personal For distribution. for Not use only. personal For distribution. for Not only. use personal For

Key to symbols Notes ➢ Further information is available at © Liverpool Drug Interactions Group, ⚫ These drugs should not be coadministered www.hep-druginteractions.org University of Liverpool, Pharmacology Research Labs, Potential clinically significant interaction that is likely to require additional ➢ Predicted interactions are based on known 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF  monitoring, alteration of drug dosage or timing of administration metabolic pathways and routes of clearance. We aim to ensure that information is accurate and consistent with current knowledge Potential interaction likely to be of weak intensity. Additional ➢ Caution is required in patients with hepatic and practice. However, the University of Liverpool and its servants or agents shall action/monitoring or dosage adjustment is unlikely to be required impairment as this may also increase drug levels not be responsible or in any way liable for the continued currency of information in and require dose modification. this publication whether arising from negligence or otherwise howsoever or for any ◆ No clinically significant interaction expected ➢ Where advice differs between countries, the consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

charts reflect the more cautious option.

www.hep-druginteractions.org

Interactions with HBV Treatment

Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 7 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF.

ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b Other Drugs Continued Oxytocics Isosorbide mononitrate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (ergonovine) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isotretinoin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lanreotide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Levothyroxine ◆ ◆ ◆ ◆ ◆  ◆ ◆ ◆ Parkinsonism Agents ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Benztropine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lumacaftor/Ivacaftor ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Carbidopa ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Magnesium ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

Orphenadrine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Melatonin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Minoxidil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Rasagiline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ PBC Agents

Nalmefene ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Obeticholic acid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ for distribution. for ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ursodeoxycholic acid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Neostigmine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nicorandil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nusinersen ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ocrelizumab ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Penicillamine ◆ ◆ ◆ ◆ ◆ ◆  ◆  (topical) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (topical) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Piracetam ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Protamine sulphate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ (topical) ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Pyridostigmine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Raloxifene ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Sevelamer ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Strontium ranelate ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Thalidomide ◆ ◆ ◆    ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Tranexamic acid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Urological Agents Varenicline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Desmopressin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not Not only. use personal For distribution. for Not use only. personal For distribution. for Not only. use personal For

Key to symbols Notes ➢ Further information is available at © Liverpool Drug Interactions Group, ⚫ These drugs should not be coadministered www.hep-druginteractions.org University of Liverpool, Pharmacology Research Labs, Potential clinically significant interaction that is likely to require additional ➢ Predicted interactions are based on known 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF  monitoring, alteration of drug dosage or timing of administration metabolic pathways and routes of clearance. We aim to ensure that information is accurate and consistent with current knowledge Potential interaction likely to be of weak intensity. Additional ➢ Caution is required in patients with hepatic and practice. However, the University of Liverpool and its servants or agents shall action/monitoring or dosage adjustment is unlikely to be required impairment as this may also increase drug levels not be responsible or in any way liable for the continued currency of information in and require dose modification. this publication whether arising from negligence or otherwise howsoever or for any ◆ No clinically significant interaction expected ➢ Where advice differs between countries, the consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

charts reflect the more cautious option.